Takeaways from #ACC2024. Late breaking trials - take home points American College of Cardiology 1. RELIEVE-HF Trial: In patients with HFrEF and HFpEF, Interatrial Shunt did not show any significant difference in the primary effectiveness endpoint, a composite of all-cause mortality, LVAD/heart

#ACC2024 #TopClinicalTrials #Summary #AtOneGlanceForYou ! 😍Terrific amount of advancement in Cardiovascular science that made us think, that made us learn and that made us evolve. ❤️🙏 American College of Cardiology #ACCFIT #LoveForHeart 💡⭐️🫀🫶👏

Always a pleasure presenting interesting cases and research alongside cofellows and friends from all over PR 🇵🇷 🙏🏼 PRChapterACC American College of Cardiology #ACCFIT #ACC

Thank you PRChapterACC 🫀🇵🇷 for the opportunity to present my case of a sinus venosus ASD with PAPVR in a middle aged Puerto Rican man that was identified and successfully repaired just in time 🤓 #ACC #ACCFIT American College of Cardiology

Jaideep The Osler Medical Residency Abhi Gami Johns Hopkins Ciccarone Center Johns Hopkins Cardiology Johns Hopkins Gupta-Klinsky India Institute (GKII) Michael J. Blaha Khurram Nasir Matthew Budoff MD Suvasini Lakshmanan Once CAC > 100 , can we call it “secondary” prevention. Even today many cardiologist not aware to treat existing plaque / CAD aggressively. Why wait for a possible fatal event?

Understanding the spectrum of #CVrisk in women. A primer on ✅Traditional RF ✅ APOs & CV RF ✅ Sex specific risk ✅ Risk @ menopause and HRT Thanks to editors Matthew Budoff MD Suvasini Lakshmanan and coauthors Anandita Agarwala Kulkarni, MD FACC Jaideep and Dr. Eleonora Avenatti bit.ly/3WyVYTd

💊 SGLT2i have benefit across a variety of cardiometabolic diseases. 🐌 Yet, adoption has been slow. Inpatient SGLT2i initiation can: 👉Improve outcomes with early initiation 👉↑Compliance 👉Enable patient education & 💊 monitoring In this state-of-the-art review in

Original Article: Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) nej.md/4coe9zv Editorial: Entering a New Era in Sleep-Apnea Treatment nej.md/3RBd13I #ADASciSessions

🚨🚨🚨 MAJOR news in the #amyloidosis world this morning with positive topline results of #HELIOS-B. #Vutrisiran met all primary & secondary endpoints. Let's break down what we know... #StanfordAmyloidCenter (1/13)

Very important findings. In asymptomatic individuals, elevated Lp(a) was not associated with CAC, but was associated with any plaque and multiple high risk features. Among CAC=0, there was a significantly higher prevalence of plaque with elevated Lp(a). ahajournals.org/doi/10.1161/CI…

#AHA24 Characteristics of the #SUMMIT population #LBCT 🫀 women enrolled! 👏🏽 🫀QoL by KCCQ improved greater in the treatment arm 🫀endpoint driven by ⤵️ HF worsening in Tx arm 🫀⤵️ in primary endpoint achieved with HR=0.62, p=0.026 This was an outcomes trial for #HFpEF NEJM

Top 🔟 Clinical Trials of 2024: 🔥 PREVENT 🔥 DanGer Shock 🔥 REDUCE-AMI 🔥 CLEAR SYNERGY (OASIS 9) 🔥 And more! Read the details of the clinical trials here: bit.ly/41Kb7nn

So much to celebrate and be grateful for this year! 🎉🤩 Board Certified in Cardiovascular Diseases ✅🏆 and elected to Fellowship in the American College of Cardiology 🫀🎓 Looking forward to ACC.25 in Chicago!!! American College of Cardiology #ACC25

Early diagnosis and treatment of FH reduces the risk of #cvCAD by 80%. Improve detection and diagnosis of FH and get to know the new treatment options for patients with ACC's online course ➡️ bit.ly/3vNLMqW #RareDiseaseDay #FamilialHypercholesterolemia #ACCEd

🫀NEW GUIDELINE🫀 Read our newest #ASEGuideline, "Guidelines for the Echocardiographic Assessment of the Right Heart in Adults and Special Considerations in Pulmonary Hypertension!" bit.ly/41pUxXV

Learn about the unique role of Lp(a) as a genetic determinant for #ASCVD risk & the importance of testing for Lp(a) levels to better understand your patients’ cardiovascular health w/ ACC's online course. ⬇️ More: bit.ly/3WmPipH #LpaAwarenessDay #KnowLpa #ACCEd

“We have a new treatment for PAD”: STRIDE trial shows #ozempic improves walking distance in pts w PAD and diabetes Novo Nordisk American College of Cardiology ACC Media Center #ACC25 #CardioTwitter

🚨 WARRIOR: 🔑 Intensive therapy did not ⬇️ MACE vs. usual care for #INOCA 🔑 #COVID limited study power; non-significant benefit shown 🔑 Data “should not be interpreted as endorsing discontinuing statin & ACE or ARB medications” for women w/ 🫀 risk factors ACC Media Center

🚨 ADVANCE-HTN: 🩸 Lorundrostat effectively ⬇️ 24-h BP in patients with uncontrolled resistant #hypertension 🩸 50-mg dose was most effective 🩸 “Drugs that target aldosterone production have great potential” Luke J. Laffin Cleveland Clinic MD American College of Cardiology ACC Media Center Endocrine Today